Ashley Shafferman James D Birmingham Randy Q Cron
10.1186/1546-0096-12-26
Pediatr Rheumatol Online J
2014 Jul 11;12:26.
anakinra interleukin-1 receptor antagonist kawasaki disease macrophage activation syndrome neonate secondary hemophagocytic lymphohistiocytosis
CC BY
https://pubmed.ncbi.nlm.nih.gov/25045337/
Antibodies, Monoclonal / administration & dosage Glucocorticoids / administration & dosage Interleukin 1 Receptor Antagonist Protein / administration & dosage Macrophage Activation Syndrome / drug therapy Macrophage Activation Syndrome / etiology Mucocutaneous Lymph Node Syndrome / complications Mucocutaneous Lymph Node Syndrome / diagnosis Mucocutaneous Lymph Node Syndrome / drug therapy Mucocutaneous Lymph Node Syndrome / physiopathology
Antibodies, Monoclonal / administration & dosage Glucocorticoids / administration & dosage Interleukin 1 Receptor Antagonist Protein / administration & dosage Macrophage Activation Syndrome / drug therapy Macrophage Activation Syndrome / etiology Mucocutaneous Lymph Node Syndrome / complications Mucocutaneous Lymph Node Syndrome / diagnosis Mucocutaneous Lymph Node Syndrome / drug therapy Mucocutaneous Lymph Node Syndrome / physiopathology Case Reports Antirheumatic Agents / administration & dosage Dose-Response Relationship, Drug Drug Monitoring Drug Therapy, Combination Early Diagnosis Early Medical Intervention Female Humans Infant Infliximab Patient Acuity Treatment Outcome Antibodies, Monoclonal Antirheumatic Agents Glucocorticoids Interleukin 1 Receptor Antagonist Protein Infliximab
PMC4103976
25045337
High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report
2014